spacer
spacer
Go to PDB code: 
protein ligands links
Growth factor PDB id
1rml
Jmol
Contents
Protein chain
131 a.a. *
Ligands
NTS
* Residue conservation analysis
PDB id:
1rml
Name: Growth factor
Title: Nmr study of acid fibroblast growth factor bound to 1,3,6- naphthalene trisulphonate, 26 structures
Structure: Acidic fibroblast growth factor. Chain: a. Fragment: residues 23 - 154. Synonym: heparin-binding growth factor 1. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562.
NMR struc: 26 models
Authors: R.M.Lozano,M.A.Jimenez,J.Santoro,M.Rico,G.Gimenez-Gallego
Key ref:
R.M.Lozano et al. (1998). Solution structure of acidic fibroblast growth factor bound to 1,3, 6-naphthalenetrisulfonate: a minimal model for the anti-tumoral action of suramins and suradistas. J Mol Biol, 281, 899-915. PubMed id: 9719643 DOI: 10.1006/jmbi.1998.1977
Date:
21-May-98     Release date:   11-Nov-98    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
P05230  (FGF1_HUMAN) -  Heparin-binding growth factor 1
Seq:
Struc:
155 a.a.
131 a.a.
Key:    PfamA domain  Secondary structure  CATH domain

 Gene Ontology (GO) functional annotation 
  GO annot!
  Cellular component     extracellular region   8 terms 
  Biological process     multicellular organismal development   22 terms 
  Biochemical function     protein binding     6 terms  

 

 
DOI no: 10.1006/jmbi.1998.1977 J Mol Biol 281:899-915 (1998)
PubMed id: 9719643  
 
 
Solution structure of acidic fibroblast growth factor bound to 1,3, 6-naphthalenetrisulfonate: a minimal model for the anti-tumoral action of suramins and suradistas.
R.M.Lozano, M.Jiménez, J.Santoro, M.Rico, G.Giménez-Gallego.
 
  ABSTRACT  
 
Recent data show that anti-angiogenesis may provide a promising route to treat cancer. Fibroblast growth factors (FGFs) are powerful angiogenic polypeptides, whose mitogenic activity requires the presence of heparin-like compounds. It has been shown that angiogenesis promoted by FGFs on inhibition by monoclonal antibodies and antisense targeting can also inhibit tumour growth. Derivatives of suramin, a polysulfonated binaphthyl urea and binaphthylsulfonated derivatives of distamycin, suradistas, constitute an important group of potential anti-cancer agents. These compounds compete with heparin in forming tight complexes with FGFs. This inhibits the recognition of these growth factors by their tyrosine kinase membrane receptors thereby suppressing their angiogenic activity. Here we show that 1,3,6-naphthalenetrisulfonate, a common chemical function of the suramins and suradistas with the highest anti-angiogenic activity inhibits the mitogenic activity of acidic fibroblast growth factor, and that this inhibition is relieved by increasing concentrations of heparin in the assay. We have also solved the three-dimensional structure in solution of the protein complexed to this compound. The structural data provide clues that may help in understanding the inhibitory effect of suramins and suradistas, and could contribute to the development of new anti-tumoral drugs.
 
  Selected figure(s)  
 
Figure 4.
Figure 4. Differences in d-values between the NH amide (A) and C^aH (B) protons for each residue in NTS and MIHS-bound aFGF.
Figure 9.
Figure 9. Surface of the mean structures of NTS (left) and MIHS-bound (right) aFGF color mapped with the electrostatic potential (red, negative; blue, positive), showing the residues, highlighted in Figure 8, that presumably interact with the tyrosine kinase cell membrane receptors. Residues whose interaction is suggested by visual inspection of the region defined by the ones identified by point-directed mutagenesis (green color in Figure 8) are labelled with an asterisk (*).
 
  The above figures are reprinted by permission from Elsevier: J Mol Biol (1998, 281, 899-915) copyright 1998.  
  Figures were selected by an automated process.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
20135044 J.L.Barneto, M.Avalos, R.Babiano, P.Cintas, J.L.Jiménez, and J.C.Palacios (2010).
A new model for mapping the peptide backbone: predicting proton chemical shifts in proteins.
  Org Biomol Chem, 8, 857-863.  
19034645 S.Cochran, C.P.Li, and V.Ferro (2009).
A surface plasmon resonance-based solution affinity assay for heparan sulfate-binding proteins.
  Glycoconj J, 26, 577-587.  
16563234 P.Cuevas, D.Díaz-González, C.García-Martín-Córdova, I.Sánchez, R.M.Lozano, G.Giménez-Gallego, and M.Dujovny (2006).
Dobesilate diminishes activation of the mitogen-activated protein kinase ERK1/2 in glioma cells.
  J Cell Mol Med, 10, 225-230.  
16175541 S.Cochran, C.P.Li, and I.Bytheway (2005).
An experimental and molecular-modeling study of the binding of linked sulfated tetracyclitols to FGF-1 and FGF-2.
  Chembiochem, 6, 1882-1890.  
12676958 C.Fernández-Tornero, R.M.Lozano, M.Redondo-Horcajo, A.M.Gómez, J.C.López, E.Quesada, C.Uriel, S.Valverde, P.Cuevas, A.Romero, and G.Giménez-Gallego (2003).
Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalene sulfonate.
  J Biol Chem, 278, 21774-21781.
PDB code: 1hkn
11920877 E.De Lorenzi, S.Grossi, G.Massolini, S.Giorgetti, P.Mangione, A.Andreola, F.Chiti, V.Bellotti, and G.Caccialanza (2002).
Capillary electrophoresis investigation of a partially unfolded conformation of beta(2)-microglobulin.
  Electrophoresis, 23, 918-925.  
11964252 M.Zamai, C.Hariharan, D.Pines, M.Safran, A.Yayon, V.R.Caiolfa, R.Cohen-Luria, E.Pines, and A.H.Parola (2002).
Nature of Interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolecarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino])-bis-(1,3-naphtalene disulfonate). II. Removal of polar interactions affects protein folding.
  Biophys J, 82, 2652-2664.  
11806921 N.Lehmann, G.Krishna Aradhyam, and K.Fahmy (2002).
Suramin affects coupling of rhodopsin to transducin.
  Biophys J, 82, 793-802.  
  11576867 A.Matter (2001).
Tumor angiogenesis as a therapeutic target.
  Drug Discov Today, 6, 1005-1024.  
11223514 H.J.Hecht, R.Adar, B.Hofmann, O.Bogin, H.Weich, and A.Yayon (2001).
Structure of fibroblast growth factor 9 shows a symmetric dimer with unique receptor- and heparin-binding interfaces.
  Acta Crystallogr D Biol Crystallogr, 57, 378-384.
PDB code: 1g82
11257129 Y.V.Fedorov, R.S.Rosenthal, and B.B.Olwin (2001).
Oncogenic Ras-induced proliferation requires autocrine fibroblast growth factor 2 signaling in skeletal muscle cells.
  J Cell Biol, 152, 1301-1305.  
10848963 M.Guzmán-Casado, J.M.Sánchez-Ruiz, M.El Harrous, G.Giménez-Gallego, and A.Parody-Morreale (2000).
Energetics of myo-inositol hexasulfate binding to human acidic fibroblast growth factor effect of ionic strength and temperature.
  Eur J Biochem, 267, 3477-3486.  
10819962 R.M.Lozano, A.Pineda-Lucena, C.Gonzalez, M.Angeles Jiménez, P.Cuevas, M.Redondo-Horcajo, J.M.Sanz, M.Rico, and G.Giménez-Gallego (2000).
1H NMR structural characterization of a nonmitogenic, vasodilatory, ischemia-protector and neuromodulatory acidic fibroblast growth factor.
  Biochemistry, 39, 4982-4993.
PDB codes: 1dzc 1dzd
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB code is shown on the right.